{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:38:35Z","timestamp":1792589915523,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We designed and synthesized a novel theranostic bisphosphonate radiopharmaceutical (<jats:sup>68<\/jats:sup>Ga- or <jats:sup>177<\/jats:sup>Lu-labeled DOTA-ibandronic acid [<jats:sup>68<\/jats:sup>Ga\/<jats:sup>177<\/jats:sup>Lu-DOTA-IBA]) for bone metastasis. In this study, the dosimetry, safety, and efficacy of <jats:sup>68<\/jats:sup>Ga\/<jats:sup>177<\/jats:sup>Lu-DOTA-IBA as a theranostic radiopharmaceutical for bone metastases were evaluated in patients with malignancy based on <jats:sup>68<\/jats:sup>Ga- and <jats:sup>177<\/jats:sup>Lu-DOTA-IBA images, blood samples, and dosimetric analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Eighteen patients with bone metastasis and progression under conventional therapies were included in this study. Baseline <jats:sup>99m<\/jats:sup>Tc-MDP SPECT and <jats:sup>68<\/jats:sup>Ga-DOTA-IBA PET\/CT were performed for comparative purposes within 3 days. After receiving 891.5 \u00b1 301.3 MBq <jats:sup>177<\/jats:sup>Lu-DOTA-IBA, serial <jats:sup>177<\/jats:sup>Lu-DOTA-IBA SPECT bone scan was performed over 14 days. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Karnofsky Performance Status, pain score, and follow-up <jats:sup>68<\/jats:sup>Ga-DOTA-IBA PET\/CT were performed for response evaluation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Baseline <jats:sup>68<\/jats:sup>Ga-DOTA-IBA PET demonstrated a higher efficacy for detecting bone metastases compared with <jats:sup>99m<\/jats:sup>Tc-MDP SPECT. The time-activity curves showed fast uptake and high retention of <jats:sup>177<\/jats:sup>Lu-DOTA-IBA in bone metastases (24 hours: 9.43 \u00b1 2.75 %IA; 14 days: 5.45 \u00b1 2.52 %IA). Liver, kidneys, and red marrow time-activity curves revealed a low uptake and fast clearance. The radiation-absorbed dose in bone metastasis lesions (6.40 \u00b1 2.13 Gy\/GBq) was significantly higher than that in red marrow (0.47 \u00b1 0.19 Gy\/GBq), kidneys (0.56 \u00b1 0.19 Gy\/GBq), or liver (0.28 \u00b1 0.07 Gy\/GBq), with all <jats:italic toggle=\"yes\">P<\/jats:italic>\u2019s &lt; 0.001. Compared with baseline level, only one patient developed new grade 1 leukopenia (toxicity rate, 6%). The <jats:sup>177<\/jats:sup>Lu-DOTA-IBA therapy had no statistically significant effect on bone marrow hematopoietic function, liver function, and kidney function at any follow-up visit. Bone pain palliation was achieved in 82% (14\/17) of patients. The 8-week follow-up <jats:sup>68<\/jats:sup>Ga-DOTA-IBA PET\/CT demonstrated partial response in 3 patients, disease progression in 1 patient, and stable disease in 14 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga\/<jats:sup>177<\/jats:sup>Lu-DOTA-IBA provides a set of potential theranostic radiopharmaceuticals and may have a good prospect for the management of bone metastasis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004634","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T17:00:31Z","timestamp":1680022831000},"page":"489-496","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":42,"title":["Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases"],"prefix":"10.1097","volume":"48","author":[{"given":"Lin","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,26]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"15024","DOI":"10.1038\/boneres.2015.24","article-title":"Contemporary approaches for imaging skeletal metastasis","volume":"3","year":"2015","journal-title":"Bone Res"},{"key":"bib2-20250621","first-page":"953","article-title":"Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases","volume":"44","year":"2003","journal-title":"J Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/rpd\/ncu237","article-title":"Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients","volume":"163","year":"2015","journal-title":"Radiat Prot Dosimetry"},{"key":"bib4-20250621","first-page":"202","article-title":"177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis","volume":"23","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/ph10020045","article-title":"Novel radiolabeled bisphosphonates for PET diagnosis and endoradiotherapy of bone metastases","volume":"10","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12149-019-01348-7","article-title":"Preliminary results of biodistribution and dosimetric analysis of [(68)Ga]Ga-DOTA(ZOL): a new zoledronate-based bisphosphonate for PET\/CT diagnosis of bone diseases","volume":"33","year":"2019","journal-title":"Ann Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13550-019-0566-x","article-title":"Biodistribution and post-therapy dosimetric analysis of [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results","volume":"9","year":"2019","journal-title":"EJNMMI Res"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2967\/jnumed.120.255851","article-title":"Evaluation of safety and dosimetry of (177)Lu-DOTA-ZOL for therapy of bone metastases","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation, biological characterization and preliminary human imaging studies of (68)Ga-DOTA-IBA","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"bib11-20250621","first-page":"71","article-title":"Pharmacokinetic, dosimetry and toxicity study of 177Lu-EDTMP in patients: phase 0\/I study","volume":"9","year":"2016","journal-title":"Curr Radiopharm"},{"key":"bib12-20250621","first-page":"46","article-title":"Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients' pain score analysis and personalized dosimetry","volume":"4","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/RLU.0b013e318279bf4d","article-title":"Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00259-014-2862-z","article-title":"(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.1989.7.12.1926","article-title":"A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases","volume":"7","year":"1989","journal-title":"J Clin Oncol"},{"key":"bib16-20250621","first-page":"1839","article-title":"Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I\/II trial","volume":"34","year":"1993","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002590050017","article-title":"Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases","volume":"27","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2385-1-2","article-title":"Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose","volume":"1","year":"2001","journal-title":"BMC Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:01:15Z","timestamp":1750532475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004634"}},"subtitle":["A Phase 0\/I Study"],"short-title":[],"issued":{"date-parts":[[2023,3,26]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004634","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,26]]}}}